An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
In an age where technology and finance intersect at lightning speed, Luana Lopes Lara, a…
In a significant development for higher education in India, Victoria University (VU) from Australia is…
Many lakes around the world are known by special names because of their stories, beauty,…
Under Section 45ZL of the Reserve Bank of India Act, 1934, every quarter, India’s Monetary…
India hosts nearly 8% of the world’s biodiversity, making conservation crucial for ecological balance and…
Swaraj Kaushal, the former Governor of Mizoram, a noted senior advocate, and the husband of…